Product image of Ipratropium Adultes Cristers (Ipratropium Bromide) supplied by GNH India

Ipratropium Adultes Cristers

Active Ingredient:
Ipratropium Bromide
Origin:
EU

Ipratropium Adultes Cristers (Ipratropium Bromide)

Ipratropium bromide, the active ingredient in Ipratropium Adultes Cristers, is an anticholinergic (muscarinic antagonist) presented as an inhalation formulation for inhalation use. It is employed to relieve bronchospasm and reduce airway secretions in patients with obstructive lung diseases such as COPD and asthma.

GNH India supplies Ipratropium Adultes Cristers as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Manufacturer / TM Owner

Cristers

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ipratropium bromide is used as a bronchodilator in obstructive airway diseases, improving airflow and reducing secretions.

  • Chronic Obstructive Pulmonary Disease (COPD): improves lung function and decreases bronchial mucus production in COPD patients.
  • Asthma (adjunct therapy): provides additional bronchodilation when combined with beta‑agonists for patients with persistent bronchospasm.
  • Bronchospasm of other obstructive conditions: reduces airway resistance and eases breathing during acute episodes.
  • Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity in patients with COPD or asthma.

How It Works

  • Ipratropium bromide acts as a competitive antagonist at muscarinic acetylcholine receptors M1 and M3 located on airway smooth muscle and submucosal glands. By blocking acetylcholine binding, it prevents intracellular calcium increase, leading to relaxation of bronchial smooth muscle and inhibition of mucus secretion, thereby producing bronchodilation and reducing airway obstruction. The effect is localized to the respiratory tract because the compound is poorly absorbed systemically, minimizing systemic anticholinergic activity.

Side Effects

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and related to its anticholinergic activity in the airways.

Common Side Effects

  • Dry mouth
  • Cough
  • Throat irritation
  • Headache
  • Dizziness

Serious or Rare Side Effects

  • Paradoxical bronchospasm
  • Angioedema
  • Severe allergic reaction (anaphylaxis)

Precautions & Warnings

Before prescribing ipratropium bromide, clinicians should evaluate patient history and monitor for potential complications associated with anticholinergic therapy.

  • Assess respiratory status: confirm diagnosis of COPD or asthma and baseline lung function.
  • Monitor for paradoxical bronchospasm: discontinue if severe worsening of breathing occurs.
  • Avoid use in patients with hypersensitivity: contraindicated in those with known allergy to ipratropium or formulation components.
  • Use with caution in narrow‑angle glaucoma: anticholinergic effect may increase intra‑ocular pressure.
  • Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Ipratropium bromide can interact with other medications, altering anticholinergic load or bronchodilator response.

Major Interactions (Avoid)

  • Concurrent use with other muscarinic antagonists (e.g., tiotropium): risk of excessive anticholinergic effects.
  • Combination with MAO inhibitors: may increase risk of hypertensive reactions.

Moderate Interactions (Monitor Closely)

  • Beta2‑agonists (e.g., albuterol): additive bronchodilation may require dose adjustment.
  • Antihistamines: may enhance dry‑mouth sensation.
  • Theophylline: monitor serum levels as ipratropium may affect metabolism.

Frequently Asked Questions

Ipratropium Adultes Cristers contains ipratropium bromide, an inhaled anticholinergic bronchodilator. It is prescribed to relieve bronchospasm and reduce mucus production in patients with chronic obstructive pulmonary disease (COPD) and asthma, helping improve airflow and ease breathing.

Ipratropium bromide blocks muscarinic (M1 and M3) acetylcholine receptors on airway smooth muscle and submucosal glands. This inhibition prevents calcium‑mediated contraction and mucus secretion, resulting in relaxation of the bronchial muscles and reduced airway obstruction.

The dose of ipratropium bromide is individualized by the prescribing clinician based on the patient’s condition, severity, and response. It is delivered via a metered‑dose inhaler or nebulizer, and the prescriber determines the number of puffs or nebulization time per day.

Safety data for ipratropium bromide in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any potential risk to the fetus. Caution is also advised during breastfeeding, and a healthcare professional should be consulted.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Ipratropium Adultes Cristers. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ipratropium is an anticholinergic bronchodilator, whereas beta‑agonists (e.g., albuterol) act on adrenergic receptors. Ipratropium provides a longer‑acting, non‑beta‑stimulating option and is often used in combination with beta‑agonists for additive bronchodilation. Compared with long‑acting muscarinic antagonists such as tiotropium, ipratropium has a shorter duration of action and may require more frequent dosing.

Store the inhalation product at room temperature, below 25 °C, in its original container. Keep it away from moisture, direct sunlight and heat sources. Do not freeze the device, and ensure the mouthpiece remains clean to maintain dose accuracy.

Ipratropium is administered by inhalation using a metered‑dose inhaler (MDI) or a nebulizer solution. The patient inhales the prescribed number of puffs or nebulizes the solution as directed by the healthcare provider, typically spaced several hours apart to maintain bronchodilation.

Serious adverse reactions, although rare, include paradoxical bronchospasm, angioedema and severe allergic responses such as anaphylaxis. If any of these occur, the medication should be stopped immediately and emergency medical care sought.

Ipratropium should be avoided in individuals with known hypersensitivity to ipratropium bromide or any component of the formulation. Caution is also advised for patients with narrow‑angle glaucoma, urinary retention, or severe gastrointestinal obstruction, as anticholinergic effects may exacerbate these conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ipratropium Bromide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT